Washington: The approval is based on a late-stage trial showing that Ozempic slashed the risk of severe kidney outcomes—including kidney failure, declining kidney function, or death from kidney or heart complications—by 24% compared with a placebo.

With 40% of Type 2 diabetes patients affected by CKD, the FDA’s decision provides a new lifeline for those at risk of kidney failure and cardiovascular disease, two of the leading causes of death in the U.S.

Patients who took Ozempic in the trial also saw:

18% reduction in major cardiovascular events like heart attacks.

20% lower risk of death from any cause.

29% drop in cardiovascular-related deaths.

The decision is expected to reshape how doctors manage CKD in diabetic patients, offering a proven therapy to slow disease progression and improve survival rates.